Samantha Truex

Saman­tha Truex's Quench Bio calls it quits af­ter fail­ing to solve the Gas­der­min D in­flam­ma­tion puz­zle

At the core of the bio­phar­ma in­dus­try is an ex­per­i­men­tal sci­ence. Every com­pa­ny and biotech out there hopes to one day prove their hy­pothe­ses and cre­ate im­pact­ful med­i­cines that can help pa­tients.

But sci­ence is messy, and some­times those ex­per­i­ments don’t end up work­ing as planned.

Quench Bio, the Cam­bridge, MA-based biotech look­ing for new ways to tar­get the gene Gas­der­min D in treat­ing in­flam­ma­to­ry dis­eases, has de­cid­ed to wind down op­er­a­tions af­ter the gene proved “un­drug­gable” with their tech­nol­o­gy. The com­pa­ny an­nounced the news in a Twit­ter thread Tues­day morn­ing, and in an ef­fort to keep Gas­der­min pro­grams mov­ing for­ward, auc­tioned off its re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.